Compares two PET scan tracers that track T cells in lung cancer patients
Compares two PET scans that track immune T cells in lung cancer before surgery.
Plain-language title generated from the registry record
Registry title: Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer
Key facts
- Where
- Amsterdam, NetherlandsSee the site
- Phase
- Phase 2/3
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC, location VUmc
- Trial code
- NCT06457789EU 2023-509486-20-00
- Record updated
- 18 August 2026
- Original description
The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor.Read full original descriptionShow less
Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer
The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor.
This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.
Inclusion: Histologically confirmed NSCLC; T1-4N0-2, lesion size of ≥2cm, at time of the restaging FDG PET/CT; Planned to undergo resection after chemo-IO according to routine treatment guidelines; Willing and able to provide written informed consent for the trial; Above 18 years of age on day of signing informed consent; Have measurable disease based on RECIST 1.1; Have a ECOG performance status of 0-1, and are considered operable based on pulmonary function test and/or exercise testing.
Exclusion: Patients who have received a splenectomy; Patients who have received any vaccination within 14 days of enrollment; Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid \>10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease; Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; Patients deemed inoperable; Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial.